Actinium Pharmaceuticals, Inc. (ATNM) |
|
5.11 -0.1 (-1.92%)
|
06-26 22:05 |
|
Open: |
5.21 |
Pre. Close: |
5.21 |
|
High:
|
5.29 |
Low:
|
5.0943 |
|
Volume:
|
221,217 |
Market Cap:
|
122(M) |
|
|
|
|
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.3 - 5.34 |
5.34 - 5.37 |
|
Low:
|
5.01 - 5.05 |
5.05 - 5.08 |
|
Close:
|
5.05 - 5.12 |
5.12 - 5.17 |
|
Technical analysis |
as of: 2022-06-24 4:38:10 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 6.49 One year: 7.13 |
| Support: |
Support1: 4.67 Support2: 3.88 |
| Resistance: |
Resistance1: 5.55 Resistance2: 6.11 |
| Pivot: |
5.13 |
| Moving Average: |
MA(5): 5.19 MA(20): 5.22
MA(100): 5.44 MA(250): 6.37 |
| MACD: |
MACD(12,26): -0.2  Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 59.7 %D(3): 58.4 |
| RSI: |
RSI(14): 43.1 |
| 52-week: |
High: 10.3 Low: 4.4 |
| Average Vol(K): |
3-Month: 948 (K) 10-Days: 166 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ATNM ] has closed above bottom band by 45.8%. Bollinger Bands are 41.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Headline News |
Sun, 26 Jun 2022
Actinium Pharmaceuticals (NYSE:ATNM) Trading Down 1.9% - Defense World
Wed, 08 Jun 2022
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Cut to “Hold” at Zacks Investment Research - Defense World
Wed, 01 Jun 2022
Stock Analysts' Upgrades for June 1st (APLT, ARHS, ASTS, ATHX, ATNM, ATTO, AURA, AVDX, BAK, BBLN) - Defense World
Wed, 01 Jun 2022
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Increased to Buy at Zacks Investment Research - Defense World
Mon, 30 May 2022
Investment Analysts' Updated EPS Estimates for May 30th (AMPS, ARCO, ASHTY, ASML, ASTL, ATNM, AUGX, AXTI, BBAI, BBD) - Defense World
Wed, 25 May 2022
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Upgraded to “Buy” by Zacks Investment Research - Defense World
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: AMEX |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
22 (M) |
|
% Held by Insiders
|
2.169e+007 (%) |
|
% Held by Institutions
|
1.4 (%) |
|
Shares Short
|
978 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.316e+007 |
|
EPS Est Next Qtl
|
-0.08 |
|
EPS Est This Year
|
-0.41 |
|
EPS Est Next Year
|
-0.25 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-2 |
|
Return on Assets (ttm)
|
83 |
|
Return on Equity (ttm)
|
-21.7 |
|
Qtrly Rev. Growth
|
1.12e+006 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-64.6 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
-1.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-22 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.08 |
|
Price to Cash Flow
|
0.8 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
860720 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-08-10 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
